From: The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis
Study | Year | Study design | Control group | Intervention | Bleeding | Bleeding events | total | Periods (months) | Quality score | |
---|---|---|---|---|---|---|---|---|---|---|
Defined a priori | Defined as used | Bleedings/patients (n/n) | ||||||||
Harter [13] | 1979 | RCT | Placebo | Aspirin 160 mg od | No | Transfusions | A: 5/19 P: 13/25 | 44 | 5 | M |
Kaegi [14] | 1975 | RCT crossover | Placebo | Sulfinpyrazone 200 mg tid | No | GI bleedings | S: 2/45 P: 1/45 | 45 | 6 | M |
Kaufman [15] | 2003 | RCT | Placebo | Aspirin 325 mg + Clopidogrel 75 mg daily | Yes | As major, intermediate and minor | A + Cl:44/104 P: 23/96 | 200 | ~ 7 | H |
Kobayashi [16] | 1980 | RCT | Placebo | Ticlopidine 100 mg bid | No | Major or serious bleeding | T: 4/47 P: 3/53 | 100 | 3 | H |
Kooistra [17] | 1994 | RCT crossover | Placebo | Aspirin 30 mg od | No | Bleeding incidents not due to HD | A:2/137 P:5/137 | 137 | 3 | M |
Liu [18] | 2016 | Prospective cohort | Control | Aspirin 100 mg od | Yes | Intracranial hemorrhage, major bleeding events (i.e. gastrointestinal bleeding) | A: 14/152 C:36/254 | 406 | 60 | 6 |
Obialo [19] | 2003 | Prospective cohort | Control | Aspirin 325 mg od | No | GI bleedings | A: 5/21 C: 0/31 | 52 | ~ 4 | 7 |
Sreedhara [20](a) | 1994 | RCT | Placebo | Dipyramidole 75 mg tid | No | GI adverse events | D: 5/29 P: 2/24 | 107 | 72? | L |
Sreedhara [20](b) | Placebo | Aspirin 325 mg daily | A: 3/26 P: 2/24 | 107 | ||||||
Sreedhara [20](c) | Placebo | Aspirin 325 mg daily + Dipyramidole 75 mg tid | A + D: 5/28 P: 2/24 | 107 | ||||||
Tayebi [21] | 2018 | RCT | Placebo | Aspirin 80 mg daily + Dipyramidole 75 mg daily | No | Major or serious bleeding | A + D: 2/20 P: 0/20 | 40 | 12 | H |